drugset / Trial / NCT03737812
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
Timeline
- Start
- 2019-02-27
- Primary completion
- 2021-01-15
- Completion
- 2021-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elezanumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Elezanumab | Monoclonal antibody | 1800 mg | Intravenous |